

COMPANY REGISTRATION NUMBER : 7225131

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
UNAUDITED FINANCIAL STATEMENTS
FOR
YEAR ENDED 30 JUNE 2024**

Charity Number : 1136067



Edmund Carr LLP
Chartered Accountants
146 New London Road
Chelmsford
Essex
CM2 OAW

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
FINANCIAL STATEMENTS**

YEAR ENDED 30 JUNE 2024

CONTENTS	PAGE
Company information	1
Trustees' annual report	2
Independent Examiner's report to the Trustees	12
Statement of financial activities	13
Balance sheet	14
Notes to the financial statements	15

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
COMPANY INFORMATION**

YEAR ENDED 30 JUNE 2024

Charity Number	1136067
Company Number	7225131
Registered Office	38-43 Lincoln's Inn Fields London WC2A 3PE

THE TRUSTEES

The Trustees of the charity are also the directors of the charity.

The Trustees who served the charity during the year were as follows:

Professor Michael Douek	President
Mr Zaed Hamady	(Demitted 6/11/2023)
Professor Jayant Vaidya	Vice President
Professor Anant Desai	Honorary Secretary
Mr Michael Shackcloth	Honorary Treasurer
Mr John Whiting	EJSO Representative
Professor Jim Khan	Meeting Secretary
Mr Avi Agrawal	
Miss Melissa Cunha	(Appointed 6/11/2023)
Professor Derek Manas	(Demitted 6/11/2023)
Mr Aaron Quyn	
Professor PG Roy	(Appointed 6/11/2023)
Mr Paul Skaife	
Mrs Abigail Tomlins	

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT
YEAR ENDED 30 JUNE 2024**

The Trustees have pleasure in presenting their report and the unaudited financial statements for the charity for the year ended 30th June 2024. The Trustees of the charity as shown above are also the directors of the charity.

OBJECTIVES AND ACTIVITIES

The Charity's objectives are:

To advance the science, practice, and art of surgical oncology for the benefit of patients with cancer; and **to promote research, training, and education in surgical oncology** for the benefit of the public, patients and the medical community, and to disseminate the useful results of that research appropriately.

The Association serves as an umbrella organisation for professionals across all surgical cancer specialties and cancer research. Additionally, the Society is dedicated to driving innovation in cancer care, supporting the training and development of the future workforce, and ensuring our activities align with the Charity Commission's guidance on public benefit.

Portfolio of BASO Prizes and Awards

The Association is proud to offer a variety of awards aimed at inspiring our junior colleagues and fostering their passion for surgical oncology, cancer research, and patient care. For more details, visit: <https://baso.org.uk/education-training.aspx>. At our annual scientific meeting, the Society continues to present the following prestigious prizes:

- **Alan Edwards Memorial Prize** is awarded to the best poster presentation.
- **Ronald Raven Presentation Prize** is awarded to the best oral paper presentation.
- **BASO~ACS Presentation Prize**, formerly known as BJS Prize, is awarded to the best oral paper presentation. As a result of a structural change, the British Journal of Surgery Society (BJSS) ceased its support for this prize. In 2019, BASO Council unanimously decided to sponsor this prize to ensure continued existence to the BJS Paper Presentation Prize awarded at the BASO Meeting.
- **BASO Trainees (poster/oral presentation) Prize** is awarded to the best poster and oral paper presentations at the BASO Trainees Meeting.

To expand its commitment to all cancer-related professionals, BASO announced the following new prizes:

- **BASO Trainees Audit/QIP Prize** to support and encourage trainees, those involved with audit and quality improvement with a view of improving care to patients, in particular, cancer patients.
- **BASO Multidisciplinary Prize** to recognise the work done by our Non-Medical Professional colleagues in supporting cancer patients. This unique award is designed to highlight any research, audit, quality improvement, health service provision/development, cancer patient pathway study, cancer survivorship study.
- **BASO Medical Student Prize** to support and encourage medical students with an interest in surgical oncology.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)
YEAR ENDED 30 JUNE 2024**

Additionally, BASO annually offers a range of prizes to encourage and promote trainees' enthusiasm for surgical oncology. These awards are presented to the trainee who delivers the best surgical oncology presentation at various surgical specialty associations' annual scientific conferences.

Over the years, BASO has established a prestigious collection of awards, recognising surgeons for their outstanding achievements and contributions to cancer surgery, research, and education.

In addition to the **Ronald Raven Lifetime Achievement Award**, **Geoff Oates Award**, and **Uccio Querci della Rovere Award**, BASO introduced the **BASO Medal for Excellence** in 2022 to commemorate the 50th anniversary of the Association's founding. This prestigious award recognises significant contributions made by individual surgeons or teams in advancing cancer care through excellence in research, clinical practice, education, and innovation.

The **BASO Medal for Excellence**, an international accolade, will be awarded every five years, with nominations open to both members and non-members. It honours exceptional contributions to cancer surgery in the UK. BASO was proud to present the inaugural medal to Professor Freddie Hamdy in July 2022.

For more details, follow the link: <https://baso.org.uk/baso~acs-conferences/baso-50thanniversary-meeting.aspx>.

BASO Grants

BASO continues to expand its portfolio of research grants to support innovative cancer research. For more information, visit: <https://baso.org.uk/education-training.aspx>.

Ronald Raven Travelling Fellowship – Established in 1993 by the Ronald Raven Trustees in memory of Ronald W Raven, the founder of the Association, this fellowship is awarded annually. BASO continues to fund this £3,000 fellowship, supporting aspiring trainees in developing their skills and experience in surgical cancer treatment.

BASO (NIHR) Research Project Grant – As a non-commercial partner with the National Institute of Health Research (NIHR), BASO successfully ran a research project grant scheme to assist surgeons in cancer-related research. Awarded projects were eligible for Clinical Research Network Support, making them eligible for inclusion in the NIHR portfolio. In 2021, BASO launched a new Research Grant in Cancer Surgery in collaboration with the Rosetrees Trust, which replaced the BASO (NIHR) Research Project Grants in 2022.

BASO/Rosetrees Research Grants in Cancer Surgery – In celebration of BASO's 50th Anniversary, the National Committee introduced a new three-year research grant partnership with the Rosetrees Trust. This collaboration provides annual grants of up to £50,000.

The first round of grants was awarded at BASO's 50th Anniversary Celebration meeting. Successful applications will be considered for inclusion in the NIHR portfolio and are encouraged to seek support from the Royal College of Surgeons of England Surgical Interventional Trials Unit (SITU).

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)
YEAR ENDED 30 JUNE 2024**

Endorsement of Regional Events

The Association strives to engage with oncologists and related societies at the regional level. Through its network of Regional Representatives, BASO has actively supported a variety of regional and national meetings throughout this accounting year.

Engagement with Medical Students

In its commitment to nurturing the next generation of surgical oncologists, the Association has opened its Trainee membership to Foundation Year Trainees and Medical Students aspiring to pursue a career in surgical oncology. BASO provides valuable support for their surgical career development through skills courses, mentoring sessions, and portfolio guidance, leveraging its extensive network of regional representatives.

The Society also actively engages with undergraduate Medical Societies by sponsoring annual meetings with the BASO Prize and hosting sponsored lectures.

BASO Trainees Group

The BASO Trainees group has consistently broadened its reach and strengthened ties with trainee groups across the UK and Europe. These collaborations have allowed us to inspire trainees in the principles of research and clinical excellence in surgical oncology, through the sponsorship of prizes and lectures at national specialty meetings. Our Trainees group remains committed to advancing research, academic training, education and fellowship opportunities.

BASO's contribution to NICE consultations and Cancer CRGs

The Society continues to make a significant impact by providing expert advice on numerous site-specific surgical cancer consultations and guidelines, as requested by NICE. Our Council members actively contribute to various Cancer Clinical Reference Groups (CRGs), offering their specialised expertise.

Additionally, the Society maintains strong relationships with surgical societies and the Royal Colleges, while continuously seeking new opportunities for collaboration.

ACHIEVEMENTS AND PERFORMANCE

The Society remains committed to supporting the training and educational needs of our colleagues while addressing the challenges faced in the post-pandemic landscape. BASO has proven the value of a unified umbrella organisation, and is actively growing its membership, expanding research collaborations through grants, and supporting educational events. With steady financial health, the Society continues to deliver successful educational meetings and initiatives.

BASO Annual Scientific Meeting

BASO 2023 delivered an exceptional program, featuring a distinguished lineup of national and international experts in cancer surgery. Themed 'Clinical & Research Excellence,' the meeting was led by BASO Immediate Past President Mr Zaed Hamady, Meeting Secretary Professor Jim Khan, and Deputy Meeting Secretary Professor Jayant Vaidya, showcasing excellence across all aspects.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)
YEAR ENDED 30 JUNE 2024**

To enhance member benefits, registration fees were subsidised for both BASO and Trainee members. Additionally, the BASO Trainees Day was held virtually, providing a valuable experience at no cost for those who registered for both days of the main BASO Meeting. This initiative was designed to maximise accessibility and participation among our valued members.

The conference was structured with dedicated plenary sessions and roundtable discussions across a wide range of disciplines, fostering a network of professionals to exchange ideas and explore learning opportunities. Feedback from surgical delegates has been overwhelmingly positive, especially with the return to in-person meetings. This format provided broader networking opportunities, particularly benefiting our junior colleagues.

The program featured a distinguished lineup of speakers and engaging sessions, including hot debates, plenary awards, abstract prizes, specialty updates, keynote talks, and the latest advancements in surgical education. Notable guest speakers included Professor John Marks, Professor Susan Moug, Professor Paul H. Sugarbaker, Professor Isabel-Teresa Rubio, Professor Lynda Wyld, and Miss Rachel Hargest, among others. The focus was on best practices in surgical oncology, offering valuable insights into surgical cancer research and management across various specialties. The meeting provided excellent learning opportunities for both experienced consultants and trainee - whether they are pursuing a career in surgical oncology or exploring other surgical disciplines.

The BASO Trainees Day featured several prominent speakers who provided valuable insights across a wide range of topics. The program offered fresh perspectives on achieving excellence in both clinical work and research, guiding future careers in surgical oncology.

Approximately 120 abstracts were submitted, with 7 abstract prizes awarded for outstanding presentations. The meeting also featured several prestigious eponymous lifetime achievement awards and orations, honouring some of the leading surgeons of our time.

The Association is committed to building on the success of this program and ensuring the financial sustainability of future BASO meetings.

European Journal of Surgical Oncology

The **EJSO**, co-owned by BASO and ESSO, continues to thrive with improved submission quality and increased article downloads. The 2023 impact factor, released in June, has risen to 3.62 (for more details, visit: https://journalinsights.elsevier.com/journals/0748-7983/impact_factor_5_year). This significant increase in citations is a testament to the outstanding work of the editorial team, led by our past President, Professor Riccardo Audisio (Editor-in-Chief).

Network and links with other organisations

The Association is actively developing and strengthening connections with other specialties. This includes establishing membership ties, offering consultations, providing mentoring opportunities, and forming partnerships for future joint conferences.

Meanwhile, the BASO Trainees Group is expanding its network and is represented on the ASiT Council. The group awards Trainee Prizes of £100 each for the most outstanding surgical oncology presentations at the Annual ASiT Conference and the SCTS Annual Meetings.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)**

YEAR ENDED 30 JUNE 2024

To foster collaborative efforts, BASO Trainees has partnered with the Dukes Club and Roux Club, and recently collaborated with BONUS and SCALPEL groups to engage medical students interested in pursuing careers in surgical oncology.

European Society of Surgical Oncology

BASO maintains a strong partnership with its European sister society, ESSO. Under the Memorandum of Understanding between the two societies, BASO members benefit from full standard membership privileges with ESSO. This includes reduced registration rates for the ESSO Annual Conference, courses, and training programs. BASO members also have the opportunity to apply for an international career development program and gain access to members-only areas on the ESSO website. Additionally, BASO members now have voting rights at the ESSO General Assembly.

National Clinical Guidelines

BASO plays a significant role in the development and updating of National Clinical Guidelines. BASO council and members are appointed as Specialist Advisors for NICE's Interventional Procedure Programmes. Additionally, BASO Trustees actively contribute to various consultations and are engaged members of multiple Cancer Commissioning Groups.

All-Party Parliamentary Group on Cancer

The BASO sits as a stakeholder at the All-Party Parliamentary Group on Cancer. As the sole organisation representing the surgical community in this group, BASO is well-positioned to engage with policymakers and advocate effectively for the interests of oncology surgeons.

Health and Social Care Committee Cancer Services Expert Panel

BASO Trustees represented at the roundtable meeting to share views on a number of pledges that government has made to improve cancer services in England. It was a productive meeting and helped voice BASO's concerns, and raised the Society's profile and engagement.

Cancer Services Committee

BASO has chaired the Royal College of Surgeons of England's Cancer Services Committee (CSC), which includes representatives from all surgical disciplines. This committee has served as a vital platform for articulating the collective views of the surgical community on cancer care issues. It has provided a forum for Surgical Oncology to present a unified stance on major concerns and has included contributions from various surgical societies, Royal Colleges, patient liaison groups, and Macmillan.

In May 2022, the CSC was temporarily paused to review its remit, functionality, and representation to the Royal College of Surgeons of England Council. Following discussions with the College, BASO Council is pleased to announce the reinstatement of the CSC. This committee remains essential for communicating a cohesive perspective on cancer care and for addressing significant issues related to the commissioning of cancer services.

We believe that the CSC's reinstatement is a significant step forward in advancing BASO's collective efforts in cancer care.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)
YEAR ENDED 30 JUNE 2024**

BASO Publications

This year, BASO supported the Health Awareness: Innovations in Oncology and Imaging campaign that launched on 28th March within the Guardian and online at:

<https://www.healthawareness.co.uk/campaign/oncology/>.

BASO~ACS contributed with an article on ["Personalising breast cancer care: ways to minimise negative impacts of treatment"](#). *Discover the latest in personalised breast cancer care and treatment options. Learn about imaging advancements and targeted therapies for improved outcomes.*

BASO Endorsed Meetings

This year, BASO endorsed the following events and meetings:

- SACLPEL, Buckingham University's Medical Student Meeting – September 2023
- Surgical Oncology in Emergency Setting – September 2023
- BASO @ Association of Surgeons of India Conference – December 2023
- 8th Portsmouth Colorectal Congress – June 2024

BASO~ACS remains committed to advancing cancer treatment, research, patient care, and the education and training of the next generation of oncologists.

FINANCIAL REVIEW

Membership

Membership of the Association has remained stable throughout the year. In response to rising operational costs due to inflation, a nominal increase in subscription fees for all categories was unanimously approved at the 2022 AGM. This adjustment ensures we can effectively manage the growing expenses.

As agreed at the 2017 AGM, BASO offers a 50% discount on Full Membership for a period of two years to BASO Trainees members who have completed their training. This benefit is available to those who have maintained continuous membership for two consecutive years as paying members.

EJSO

Profits from the *EJSO* are applied to offset the cost of membership subscriptions to the journal, which are included in the final reconciliation.

In 2023, the journal generated a healthy profit for BASO~ACS, with an income of £110,212 after deducting BASO's membership subscription for the year.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)**

YEAR ENDED 30 JUNE 2024

Revenue from electronic institutional subscriptions, through e-only licenses and collections, continues to grow steadily. However, as anticipated, print revenues have declined as more customers opt for online access. The number of authors choosing to fund Open Access articles has significantly increased, leading to substantial growth in revenue from this source. BASO members continue to enjoy a 30% reduction in Open Access fees.

It is hoped that the EJSO will continue to grow under the editorship of Professor Riccardo A Audisio.

BASO Grants and Prizes

1. **BASO/Rosetrees Research Grants in Cancer Surgery 2023** is awarded to:

- Mr Chase Ng for study '*Low-Cost Virtual Reality Surgical Simulator Versus Traditional Surgical Training in Training Novice Surgeons to Perform Radical Abdominal Hysterectomy for Early-Staged Cervical Cancer: A Feasibility Randomised Clinical Trial*'.
- Miss Sarah Epton for study '*Improving Oesophago-Gastric Cancer Care by Identifying the Crucial Quality Indicators Necessary to Achieve Optimal Outcomes*'.

2. **Ronald Raven Travelling Fellowship Grant 2023** – Unfortunately, due to a lack of suitable applications, no travelling fellowships were awarded in 2023.

3. **BASO Trainees Prize** were awarded at the following external meetings:

- SCTS Annual Scientific Meeting
- ASiT Annual Conference
- BONUS Annual Meeting
- SCALPEL Meeting
- BASO Trainees Research Forum

BASO Annual Meeting 2023

BASO Trustees firmly believe that the Charity continues to fulfil its objectives by promoting and supporting advancements in surgical oncology research and education, as demonstrated by yet another successful meeting.

The meeting was supported by industry sponsorship; however, due to higher logistical costs associated with hosting in London, the 2023 Annual Conference incurred a planned loss. This was accounted for, as the National Committee made a strategic decision to fully sponsor the trainees' meeting and offer subsidised registration for junior members. It was agreed that a successful meeting was essential to fulfilling our charitable aims and would likely contribute to increased membership in the Society.

The conference elevated the Association's presence in cancer research, fostered engagement with various organisations and groups, and provided an excellent networking platform for BASO members, leading to the recruitment of new members. The Association maintains strong reserves and has secured a new income stream through the EJSO, allowing us to continue investing in education, training, and research through our Annual Conferences. However, we aim to transition towards a cost-neutral financial model in the future.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)
YEAR ENDED 30 JUNE 2024**

Reserves Policy

BASO ~ ACS holds a sufficient reserve to allow the society to meet financial obligations in the event of a financial loss following an annual conference, to maintain the low level of conference fees for delegates and to obviate the need for increases in Membership fees. The level of reserves, and income from conferences and subscriptions, is crucial to the Association's work and objectives, and is monitored carefully to ensure a balance between a secure financial position for the Association and minimal costs to Members and potential Members.

Investment Policy

The Trustees have power under the Articles to invest funds in the same manner and subject to the same conditions as the Trustees of a trust are permitted to do by the Trustee Act 2000. The Association currently holds its reserves across three deposit accounts: BASO ~ ACS holds reserves in a Scottish Widows 90-day notice account; an instant access account with Lloyds TSB; and a further instant access account with Virgin Money. BASO Trustees are looking into new investment opportunities for the Association's reserves.

STRUCTURE, GOVERNANCE AND MANAGEMENT

On 1st July 2010 a transfer was made from the unincorporated charity, BASO ~ The Association for Cancer Surgery, to the company limited by guarantee of the same name (Company number: 7225131, Limited by Guarantee and Registered as Charity No 1136067). The company was incorporated on the 15th April 2010 when new Articles were established. Simultaneous transfers were made to the new Association of Breast Surgery, which is also a company limited by guarantee (Company No 7207053 and Registered as Charity 1135699). The two Associations are thus legally independent of each other, with a service agreement between the two Associations to allow for the provision of a shared office and administration. Whilst the degree of separation has increased over time to allow both Associations to evolve and develop their individual identities, they share many goals and continue to work cooperatively together.

In May 2020, both Associations separated their joint database and IT services while agreeing to retain historical records of joint members, as well as members of ABS who attended BASO events and vice versa. The service agreement is subject to periodic review to ensure its continued relevance and fairness to both Associations. At this stage, no further significant changes are anticipated.

The Ordinary Members of the BASO~ACS National Committee and the Honorary Officer position of Vice President (who are also Trustees and Directors) are elected by a ballot of the Membership of the Association, following a 'Call for Nominations'. Officer posts (bar the Vice President position) are notified to the Membership by a call for nominations, followed by a ballot of Trustees if there is more than one candidate. All Honorary Officers are also Trustees and Directors. All appointments are confirmed by the Membership at the AGM.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)**

YEAR ENDED 30 JUNE 2024

BASO~ACS has National Committee meetings four times a year. The main business of BASO~ACS is decided upon at its National Committee meetings. Decisions in-between times are made by phone or e-mail communication between the Honorary Officers, with day-to-day issues being dealt with by the Association Manager in liaison with the Honorary Officers. The Trustees/Directors regularly review the major risks that the charity faces and its reserve policy, combined with an annual internal audit of the controls over key financial systems, which are designed to provide sufficient resources in the event of adverse conditions. No major risks have been identified by the Trustees during the year.

The Trustees pay due regard to the Charity Commission's guidance on public benefit when deciding what activities the Charity should undertake.

PLANS FOR THE FUTURE

Expanding core membership and the range of specialisms represented were outlined as key objectives for 2023-24. Although overall growth has not materialized, membership numbers have remained stable. The Trustees are actively working to strengthen ties with other Associations, many of which have been invited to nominate observers to Council meetings. In turn, BASO has offered to send observers to their meetings, aiming to enhance communication and understanding in areas of shared interest. Several Associations have shown interest, and the Trustees look forward to reporting progress in this area. The current Trustees represent a wide array of specialisms, bringing a valuable breadth of experience and perspectives to the steering process.

BASO Trustees also plan to establish affiliation support for smaller, complex cancer surgical groups by offering them affiliation to BASO membership and endorsement of their meetings. This will further expand the Association's role as the umbrella Society for all cancer surgeons.

BASO made significant contributions to consultations organized by NICE. Trustees are actively building collaborations with Royal Colleges, Cancer Commissioning Boards, Public Health England, the GMC, and other stakeholders. These partnerships aim to share knowledge, stimulate debate, and enhance best practices for the benefit of cancer patients.

In addition, BASO will continue funding research grants in partnership with the Rosetrees Trust to support surgical oncology research. This initiative aims to broaden the scope of surgical research, with shortlisted studies eligible for inclusion in the NIHR portfolio.

BASO will extend its sponsorship and support to regional meetings and Student Surgical Societies, further fostering engagement.

BASO Trainees membership is now open to Medical Students and Foundation Year Trainees interested in surgical oncology. The goal is to support their education, training, and career development in cancer surgery.

As healthcare evolves and training pressures increase, BASO Trainees aim to improve the training experience and professional competence of surgical trainees interested in oncology, particularly in academic and research domains.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
TRUSTEES' ANNUAL REPORT (continued)**

YEAR ENDED 30 JUNE 2024

This report has been prepared having taken advantage of the small companies exemption in the Companies Act 2006.

Approved by the Trustees on 4 November 2024 and signed on their behalf by:

Michael Shackcloth

.....
Mr Michael Shackcloth
Honorary Treasurer

COMPANY LIMITED BY GUARANTEE
INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES
YEAR ENDED 30 JUNE 2024

I report to the charity trustees on my examination of the accounts of the company for the year ended 30 June 2024 which are set out on pages 13 to 20.

Responsibilities and basis of report

As the charity trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your company's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Alex Stone

.....
Alex Stone FCCA

Edmund Carr LLP
146 New London Road
Chelmsford
CM2 0AW

6 February 2025

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

**STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND
EXPENDITURE ACCOUNT)**

YEAR ENDED 30 JUNE 2024

		Unrestricted Funds	Restricted Funds	Total Funds 2024	Total Funds 2023
	Note	£	£	£	£
INCOME from:					
Donations - Rosetrees Trust		-	25,000	25,000	25,000
Charitable activities:					
Members' subscriptions		34,726	-	34,726	34,442
BASO Conference and Meetings	2	33,780	-	33,780	38,445
Publications - EJSO		120,040	-	120,040	111,143
Other trading activities		-	-	-	-
Investments	3	2,676	1,831	4,507	1,497
TOTAL INCOME		<u>191,222</u>	<u>26,831</u>	<u>218,053</u>	<u>210,527</u>
EXPENDITURE on:					
Charitable activities					
Subscriptions - ESSO		9,773	-	9,773	9,165
BASO Conference and Meetings	2	51,038	-	51,038	65,896
Publications - EJSO		9,828	-	9,828	12,509
Fellowships & awards	4	26,418	24,500	50,918	57,027
National Committee and support costs	5	99,464	-	99,464	95,296
TOTAL EXPENDITURE		<u>196,521</u>	<u>24,500</u>	<u>221,021</u>	<u>239,893</u>
NET INCOME/(EXPENDITURE)		(5,299)	2,331	(2,968)	(29,366)
Transfers between funds		-	-	-	-
NET MOVEMENT IN FUNDS		(5,299)	2,331	(2,968)	(29,366)
RECONCILIATION OF FUNDS					
Total funds brought forward		254,485	26,273	280,758	310,124
Total funds carried forward		<u>249,186</u>	<u>28,604</u>	<u>277,790</u>	<u>280,758</u>

The charity has no recognised gains or losses other than the results for the period as set out above.

The notes on pages 15 to 20 form part of these financial statements.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
BALANCE SHEET
AS AT 30 JUNE 2024**

		2024		2023	
	Note	£	£	£	£
FIXED ASSETS					
Tangible assets	10		292		389
CURRENT ASSETS					
Debtors	11	43,986		10,685	
Cash at bank		335,855		356,089	
		<u>379,841</u>		<u>366,774</u>	
CREDITORS: Amounts falling due within one year	12	<u>(102,343)</u>		<u>(86,405)</u>	
NET CURRENT ASSETS			277,498		280,369
TOTAL ASSETS LESS CURRENT LIABILITIES/ NET ASSETS			<u>277,790</u>		<u>280,758</u>
FUNDS					
Unrestricted	13		249,186		254,485
Restricted	14		28,604		26,273
TOTAL FUNDS			<u>277,790</u>		<u>280,758</u>

For the year ending 30 June 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006 and with the Financial Reporting Standard (FRS102) (effective 1 January 2019).

These financial statements were approved by the Trustees on 4 November 2024 and are signed on their behalf by:

Michael Douek
.....
PROFESSOR MICHAEL DOUEK

Michael Shackcloth
.....
MR MICHAEL SHACKCLOTH

Company Registration Number: 7225131

The notes on pages 15 to 20 form part of these financial statements.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2024

1. ACCOUNTING POLICIES

Basis of accounting

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

BASO - The Association for Cancer Surgery meets the definition of a public benefit entity under FRS102. Assets and Liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes. The financial statements are prepared in sterling, which is the functional currency of the charity, and rounded to the nearest £. The charity is a company limited by guarantee.

Going Concern

The financial statements have been prepared on a going concern basis as the Trustees believe that no material uncertainties exist. The Trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure is sufficient with the level of reserves for the charity to be able to continue as a going concern.

Incoming Resources

Income from conferences held during the year is accounted for on an accruals basis. Membership subscriptions are recognised on receipt.

Resources Expended

All expenditure is accounted for on an accruals basis and includes VAT as the charity is not VAT registered. The majority of costs are attributable to specific charitable activities (ie conferences/awards). Fellowships and awards are accounted for in the period in which they are notified to the recipient. Governance costs are associated with the governance arrangements of the charity.

Debtors and creditors

Trade and other debtors are recognised at the settlement amount due. Creditors are recognised at their settlement amount.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and deposits.

Fixed Assets and Depreciation

Fixed assets are shown at historical cost. Expenditure on tangible fixed assets is capitalised. The cost of other items is written off as incurred.

Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:

Computer equipment	25% reducing balance
Fixtures & fittings	25% reducing balance

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 30 JUNE 2024**

ACCOUNTING POLICIES continued

Fund accounting

Funds held by the charity are either:

Unrestricted general funds – these are funds which can be used in accordance with the charitable objects at the discretion of the trustees.

Restricted funds – these are funds that can only be used for particular restricted purposes within the objects of the charity.

2. CHARITABLE ACTIVITIES

SCIENTIFIC CONFERENCE AND MEETINGS

	Unrestricted Funds	Restricted Funds	Total Funds 2024	Total Funds 2023
	£	£	£	£
Income				
BASO Conference Fees	31,780	-	31,780	28,945
Lecture grants	2,000	-	2,000	2,000
Other meetings	-	-	-	7,500
	<u>33,780</u>	<u>-</u>	<u>33,780</u>	<u>38,445</u>
Expenditure				
BASO Conference	50,899	-	50,899	43,013
BASO 50th Anniversary Meeting	-	-	-	12,456
Other meetings	139	-	139	10,427
	<u>51,038</u>	<u>-</u>	<u>51,038</u>	<u>65,896</u>

3. INVESTMENT INCOME

All of the charity's investment income arises from interest bearing deposit accounts.

4. FELLOWSHIPS & AWARDS

	Unrestricted Funds	Restricted Funds	Total Funds 2024	Total Funds 2023
	£	£	£	£
Ronald Raven Prize	-	600	600	600
Ronald Raven Travel Scholarships	-	-	-	3,000
Alan Edwards Memorial Fund	-	400	400	400
BASO/Rosetrees Research Grant	25,000	25,000	50,000	50,000
Other awards and medals	1,418	-	1,418	3,027
Unclaimed awards released	-	(1,500)	(1,500)	-
	<u>26,418</u>	<u>24,500</u>	<u>50,918</u>	<u>57,027</u>
2023	28,027	29,000	57,027	

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE**

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 JUNE 2024

5. NATIONAL COMMITTEE & SUPPORT COSTS

	Unrestricted Funds	Restricted Funds	Total Funds 2024	Total Funds 2023
	£	£	£	£
Staff salaries and pension costs	55,390	-	55,390	53,206
National committee costs	12,784	-	12,784	2,058
Other support costs	19,042	-	19,042	16,352
Governance costs (note 6)	12,248	-	12,248	23,680
	<u>99,464</u>	<u>-</u>	<u>99,464</u>	<u>95,296</u>
2023	95,296	-	95,296	

6. GOVERNANCE COSTS

	Unrestricted Funds	Restricted Funds	Total Funds 2024	Total Funds 2023
	£	£	£	£
Accounting and payroll services	4,123	-	4,123	3,919
Independent examination fee	650	-	650	620
Fees payable to independent examiner	4,773	-	4,773	4,539
Bank charges	510	-	510	389
Legal and professional fees	6,965	-	6,965	18,752
	<u>12,248</u>	<u>-</u>	<u>12,248</u>	<u>23,680</u>

7. STAFF COSTS AND EMOLUMENTS

Total staff costs were as follows:

	2024	2023
	£	£
Wages & salaries	49,500	48,726
Pension costs (defined contribution scheme)	5,890	4,480
	<u>55,390</u>	<u>53,206</u>

Particulars of employees:

The average number of employees during the year was 1, (full-time equivalent - 0.8)
(2023 - 1 employee and 0.8 FTE)

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 30 JUNE 2024**

8. NET OUTGOING RESOURCES FOR THE YEAR

	2024	2023
	£	£
This is stated after charging:		
Depreciation	97	177

9. TRUSTEES' REMUNERATION

None of the Trustees were paid any remuneration by the Association during the period.
Trustees are reimbursed reasonable expenses incurred when acting on behalf of the company.
Expenses totalling £4,895 were reimbursed to 11 trustees during the period
(2023 - £848 to 5 Trustees).

10. TANGIBLE FIXED ASSETS

	Computer equipment £	Fixtures & fittings £	Total £
COST			
At 1 July 2023	2,691	611	3,302
Additions	-	-	-
Disposals	-	-	-
At 30 June 2024	<u>2,691</u>	<u>611</u>	<u>3,302</u>
DEPRECIATION			
At 1 July 2023	2,302	611	2,913
Charge for the year	97	-	97
Disposals	-	-	-
At 30 June 2024	<u>2,399</u>	<u>611</u>	<u>3,010</u>
NET BOOK VALUE			
At 30 June 2024	<u>292</u>	<u>-</u>	<u>292</u>
At 30 June 2023	<u>389</u>	<u>-</u>	<u>389</u>

11. DEBTORS

	2024	2023
	£	£
Trade debtors	410	-
Prepayments and accrued income	24,656	10,685
Other Debtors	18,920	-
	<u>43,986</u>	<u>10,685</u>

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS**

YEAR ENDED 30 JUNE 2024

12. CREDITORS: Amounts falling due within one year

	2024	2023
	£	£
Trade creditors	2,301	-
Grants payable	30,000	20,715
Accruals	8,650	5,602
Deferred income	61,392	60,088
	<u>102,343</u>	<u>86,405</u>

Deferred income relates to EJSO royalties received in advance for the following period.

13. UNRESTRICTED FUNDS

Current year	Movement in resources:				Balance at 30/06/2024
	Balance at 01/07/2023	Incoming	Outgoing	Transfers	
	£	£	£	£	£
General unrestricted funds	<u>254,485</u>	<u>191,222</u>	<u>(196,521)</u>	<u>-</u>	<u>249,186</u>
Prior year	Balance at	Incoming	Outgoing	Transfers	Balance at
	01/07/2022	£	£	£	30/06/2023
	£	£	£	£	£
General unrestricted funds	<u>280,620</u>	<u>184,758</u>	<u>(210,893)</u>	<u>-</u>	<u>254,485</u>

14. RESTRICTED FUNDS

Current year	Movement in resources:				Balance at 30/06/2024
	Balance at 01/07/2023	Incoming	Outgoing	Transfers	
	£	£	£	£	£
a) Alan Edwards Memorial Fund	4,931	373	(400)	-	4,904
b) Ronald Raven Prize Fund	1,567	270	(600)	-	1,237
c) Ronald Raven Travelling Fund	19,775	1,188	1,500	-	22,463
d) BASO/Rosetrees Fund	-	25,000	(25,000)	-	-
	<u>26,273</u>	<u>26,831</u>	<u>(24,500)</u>	<u>-</u>	<u>28,604</u>

a)-c) Prize funds: An award made from the Ronald Raven Travelling Fund in 2021 was not claimed by the recipient and has been withdrawn.

d) Donations from the Rosetrees Trust towards the joint BASO/Rosetrees Research grants.

**BASO - THE ASSOCIATION FOR CANCER SURGERY
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 30 JUNE 2024**

14. RESTRICTED FUNDS

<i>Prior year</i>	<i>Movement in resources:</i>				<i>Balance at 30/06/2023</i>
	<i>Balance at 01/07/2022</i>	<i>Incoming</i>	<i>Outgoing</i>	<i>Transfers</i>	
	£	£	£	£	£
a) <i>Alan Edwards Memorial Fund</i>	5,178	153	(400)	-	4,931
b) <i>Ronald Raven Prize Fund</i>	1,876	291	(600)	-	1,567
c) <i>Ronald Raven Travelling Fund</i>	22,450	325	(3,000)	-	19,775
d) <i>BASO/Rosetrees Fund</i>	-	25,000	(25,000)	-	-
	<u>29,504</u>	<u>25,769</u>	<u>(29,000)</u>	<u>-</u>	<u>26,273</u>

15. ANALYSIS OF NET ASSETS (between restricted and unrestricted funds)

Current year	Tangible fixed assets	Other net assets	Total
	£	£	£
Restricted funds	-	28,604	28,604
Unrestricted funds	292	248,894	249,186
	<u>292</u>	<u>277,498</u>	<u>277,790</u>
<i>Prior year</i>	<i>Tangible fixed assets</i>	<i>Other net assets</i>	<i>Total</i>
	£	£	£
<i>Restricted funds</i>	-	26,273	26,273
<i>Unrestricted funds</i>	389	254,096	254,485
	<u>389</u>	<u>280,369</u>	<u>280,758</u>

16. COMPANY LIMITED BY GUARANTEE

The company is controlled by its members. Every member of the company undertakes to contribute to the assets of the Company in the event of the same being wound up during the time he/she is a member, or within one year afterwards, for the payments of the debts and liabilities of the company contracted before the time at which he/she ceases to be a member and of the costs, charges and expenses of winding up the same, and for the adjustments of the rights of the contributors among themselves such amount as may be required not exceeding one pound.

17. RELATED PARTY TRANSACTIONS

There were no related party transactions that require disclosure during the year other than the reimbursement of expenses to Trustees, disclosed in Note 9.